UCBJF
PINK UCB S.A.$240.24 ↑ +4.30 (+1.82%) Trading Up from the previous close of $235.94, and at the day’s high of $240.24
- YTD change
- -18.17%
- vs 20-day SMA
- -0.23%
- vs 200-day SMA
- -16.40%
Price ranges
Price & Performance
-88.06 (-26.82%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 30.4% away from all-time highs of $345.39
- UCBJF is down 18% since the beginning of the year
- UCBJF is down 22% over the past 12 months
- UCBJF is down 2% over the past 1 month
- 1% of all UCBJF investors are betting against UCBJF
UCBJF reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is -21.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +1.39%
- vs 8-day SMA
- +1.61%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.